See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

You Are Viewing Presentations

SCCM 2024
Cefiderocol

Cefiderocol activity for carbapenem-non-susceptible bacteria from intensive care pneumonia patients

ESCMID 2024
Cefiderocol

Cefiderocol MIC against cefiderocol-resistant Acinetobacter baumannii can be affected by starting inoculum size

IDWeek 2025
Cefiderocol

Cefiderocol remains active against US clinical isolates of Stenotrophomonas maltophilia non-susceptible to comparator agents: results from the SENTRY antimicrobial surveillance program (2020–2024)

IDWeek 2024
Cefiderocol

Cefiderocol remains highly active against carbapenemase-producing Enterobacterales

IDWeek 2024
Cefiderocol

Cefiderocol retains in vitro activity against Enterobacterales non-susceptible to β-lactam-β-lactamase inhibitor combinations

NACFC 2025
Cefiderocol

Cefiderocol treatment for gram-negative bacterial infections in patients with cystic fibrosis: results from the multinational observational PROVE study

You Are Viewing Congress Locations